A broader tissue-agnostic analysis of zenocutuzumab in the eNRGy study and early access program included 99 patients with NRG1 + solid tumors across multiple histologies, such as NSCLC (41 patients), PDAC (18 patients), breast cancer (5 patients), CCA (3 patients), and CRC (2 patients) [78]. This evidence concerns the gene NRG1 and non-small cell lung carcinoma.